Antileukoprotease: An endogenous protein in the innate mucosal defense against fungi

Journal of Infectious Diseases

Volumn 176, Issue 3, 1997, Pages 740-747

  Tomee, J F Chris ^a   Hiemstra, Pieter S ^c   Heinzel Wieland, Regina ^b   Kauffman, Henk F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b DARMSTADT UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c Fachbereich Chemische Technologie ^*

Author keywords

[No Author keywords available]

Indexed keywords

DEFENSIN; LYSOZYME; PROTEINASE INHIBITOR;

AMINO TERMINAL SEQUENCE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; HOST RESISTANCE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; YEAST CELL;

EID: 0000463507     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514098     Document Type: Article

References (14)

1. Lehrer RI, Ganz T. Antimicrobial polypeptides of human neutrophils. Blood 1990;76:2169-81.
2. Santhanagopalan V, Hahn BL, Sohnle PG. Resistance of zinc-supplemented Candida albicans cells to the growth inhibitory effect of calprotectin. J Infect Dis 1995;171:1289-94.
3. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol administration of α1-antitrypsin to suppress the burden of active neutrophil elastase on the respiratory epithelial surface in cystic fibrosis. Lancet 1991;337: 392-4.
4. Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonizes Pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990;86:300-8.
5. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992;90:1296-301.
6. Pellegrini A, Thomas U, von Fellenberg R, Wild P. Bactericidal activities of lysozyme and aprotinin against gram-negative and gram-positive bacteria related to their basic character. J Appl Bacteriol 1992;72: 180-7.
7. Bjöck L, Åkesson P, Bohus M, et al. Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor. Nature 1989;337:385-6.
8. Kramps JA, Franken C, Dijkman JH. ELISA for quantitative measurement of low-molecular-weight bronchial protease inhibitor in sputum. Am Rev Respir Dis 1984;129:959-63.
9. Wiedow O, Young JA, Davison MD, Christophers E. Antileukoprotease in psoriatic scales. J Invest Dermatol 1993;101:305-9.
10. Lee CH, Igarashi Y, Hohman RJ, Kaulbach H, White MV, Kaliner MA. Distribution of secretory leukoprotease inhibitor in the human nasal airway. Am Rev Respir Dis 1993;147:710-6.
11. Ohlsson M, Fryksmark U, Polling A, Tegner H, Ohlsson K. Localization of antileukoprotease in the parotid and the submandibular salivary glands. Acta Otolaryngol (Stockh) 1984;98:147-51.
12. Dijkman JH, Kramps JA, Franken C. Antileukoprotease in sputum during bronchial infections. Chest 1986;89:731-6.
13. Seemuller U, Arnhold M, Fritz H, et al. The acid-stable proteinase inhibitor of human mucous secretions (HUSI-I, antileukoprotease). Complete amino acid sequence as revealed by protein and cDNA sequencing and structural homology to whey proteins and Red Sea turtle proteinase inhibitor. FEBS Lett 1986;199:43-8.
14. Franken C, Meijer CJ, Dijkman JH. Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 1989;37: 493-8.